Document is current
Any future updates will be listed below
-
Authors
Khan, Sam
Hatton, Nathaniel
Tough, Daniel
Rintoul, Robert C.
Pepper, Coral
Calman, Lynn
McDonald, Fiona
Harris, Clare
Randle, Amelia
Turner, Michelle C.
Haley, Ruth A.
Rawlinson, Janette
Crosbie, Philip A. J.
McCaughan, Frank
Hatton, Matthew https://orcid.org/0000-0003-2778-7926
- License Information
-
More Information
Article History
Received: 5 April 2023
Revised: 19 June 2023
Accepted: 28 June 2023
First Online: 20 July 2023
Competing interests
: SK: no competing interests to declare. NH: no competing interests to declare. DT: no competing interests to declare. RCR: Speaker honoraria from Inivata, Astra-Zeneca, Janssen, Olympus Medical, VJ Oncology. Research funding from Owlstone Medical, Victor Dahdaleh Charitable Foundation, Cancer Research UK, Asthma and Lung UK. CP: no competing interests to declare. LC: no competing interests to declare. FMcD: no competing interests to declare. CH: no competing interests to declare. AR: no competing interests to declare. MCT: no competing interests to declare. RAH: no competing interests to declare. JR: member of NCRI lung network and patient advocate forum, BTOG steering committee, ELF LC PAG, ERS LC task force, EORTC LC group and patient panel, UK LC CEG, NHSE lung screening advisory group. PAJC: no competing interests to declare. FMcC: has current laboratory research funding from Janssen Biotech and collaborations with AstraZeneca. MH: Speaker Honorarium from Boehringer Ingelheim, MSD, AstraZeneca, Takeda.
: Consent was obtained for participation in the group events and for the results to be published as a review.
: Consent for publication was sought from the authors of the paper.
